Annovis Bio Inc

Research Annovis Bio Inc (ANVS) on Bullrun: market cap USD 79.13M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerANVS
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 79.13M
• Financial periodFY2025
• Net income-USD 28.85M

Valuation Snapshot

latest market cap is USD 79.13M.

About Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke;

Frequently asked questions

What is Annovis Bio Inc's market cap?

Annovis Bio Inc's market capitalization is USD 79.13M.

What does Annovis Bio Inc do?

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.